Micro Interventional Devices Receives FDA Breakthrough Device Designation for the MIA™-T Percutaneous Tricuspid Annuloplasty System
MID develops proprietary Transcatheter Cardiac Repair (TCR) technologies addressing unmet needs in the treatment of structural heart disease. The company's products are designed to achieve surgical efficacy with percutaneous safety.
Micro Interventional Devices Submits CE Mark Technical Documentation for the MIA-T Percutaneous Tricuspid Annuloplasty System
The receipt of a CE Mark would allow MID to commercialize MIA-T in the European Union in countries governed by the European Medical Device Regulations (MDR). MID is anticipating an approval in 2021.
Micro Interventional Devices, Inc.™ Successfully Treats First-in-Human Patient with Percutaneous MIA™, Minimally Invasive Annuloplasty Technology
"The percutaneous MIA system has the potential to be a safe and effective intervention for patients with moderate to severe tricuspid regurgitation," stated Prof. Audrius Aidieitis, MD.